Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Closes
- Jan 28, 2028 (in 562 days)
- Last verified
- Jul 15, 2026
Classification and identifiers
- Solicitation number
- PAR-25-383
- Assistance listing (CFDA)
- 93.279
Amount
Amount not published by the funder
Who can apply
Public colleges and universities, Private colleges and universities, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained thro...